June 2014 - In This Issue:
Big Ten CRC member institution,

The Big Ten CRC Administrative Headquarters would like to thank all who participated in the BTCRC meetings at ASCO. It was good to meet so many of you face to face and receive your feedback regarding BTCRC initiatives. We look forward to our continued partnership as we move closer toward opening our first trial.


Zoe Holt
BTCRC Senior Clinical Project Manager
Clinical Trial Working Groups
Goal for 2014: One concept from each institution.

Please contact Jessica Roy, Research Development Director, at [email protected] or 317-634-5842 ext. 19, to join  a clinical trial working group or submit a concept.

Thank you to everyone who attended the face-to-face working group meetings at ASCO. Your input and leadership are greatly appreciated.

GU:
  • Two approved LOIs: Prostate (University of Michigan) and renal cell carcinoma (University of Illinois).
  • New concept: Prostate (Indiana University).
Thoracic:
  • Concept: Non-small cell lung cancer (Indiana University).
  • New concept: Non-small cell lung cancer (University of Michigan).
  • New concept: Small cell lung cancer (University of Nebraska). Ad hoc call will be held on 6/12/14 to further discuss this concept.
GI:
  • Approved LOI: hepatocellular (Indiana University). 
Breast:
  • Kick-off teleconference held May 21, 2014.
  • Concept: Triple negative metastatic breast cancer (Penn State).
  • New concept: Triple negative metastatic breast cancer (Rutgers CINJ).
New Big Ten CRC trial concepts emerge from ASCO meetings

Representatives of Big Ten Cancer Research Consortium (BTCRC) member institutions gathered during ASCO 2014 for a series of meetings that produced new trial concepts and laid the groundwork for further developments in the BTCRC. Read more.

 
Big Ten CRC names executive officer

The Big Ten Cancer Research Consortium (BTCRC) announces the appointment of Susan Goodin, PharmD, as executive officer of the consortium.

 

Dr. Goodin is executive director of statewide affairs at Rutgers Cancer Institute of New Jersey and professor of medicine at Rutgers Robert Wood Johnson Medical School. She possesses more than 20 years of clinical research leadership experience including serving as the deputy director of operations, associate director of clinical trials and therapeutics, and director of the Division of Pharmaceutical Sciences at the Cancer Institute of New Jersey. She played a key role in the establishment of the Cancer Institute's clinical practice and designed its clinical research infrastructure, including the Center's research office, research pharmacy, and protocol review and monitoring system and is a founding co-leader of the Cancer Institute of New Jersey's statewide clinical trials network that includes 15 hospitals under the Center's clinical research infrastructure. Read more.
Featured Member Profile
Learn about the Fred & Pamela Buffett Cancer Center (University of Nebraska), our featured member for the month of June. Read more.
STAY CONNECTED

Like us on Facebook   Follow us on Twitter